American Academy of Neurology May 14 2025 To help neurologists, clinicians and families understand the current evidence for a new gene therapy for Duchenne muscular dystrophy called delandistrogene moxeparvovec, the American Academy of Neurology (AAN) has issued an Evidence in Focus article, published May 14, 2025, online in Neurology ® . AAN Evidence in Focus articles highlight the strength of the current evidence for new therapies for neurological conditions. Their purpose is not to provide